140 related articles for article (PubMed ID: 32828115)
21. Investigating the role of IL-33 in the pathogenesis of Behçet's Disease.
Çerçi P; Altıner S; İnal A; Köse K; Keskin G; Ölmez Ü
Acta Clin Belg; 2017 Dec; 72(6):434-438. PubMed ID: 28412856
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
De Luca G; Cariddi A; Campochiaro C; Vanni D; Boffini N; Tomelleri A; Cavalli G; Dagna L
Rheumatology (Oxford); 2020 Jan; 59(1):171-175. PubMed ID: 31280296
[TBL] [Abstract][Full Text] [Related]
23. Does lowering hyperhomocysteinemia by folic acid beneficial for oculo-Behcet's disease? A pilot study.
Houman MH; Naffati H; Khanfir M; Ghannouchi M; Ben Ghorbel I; Lamloum M; El Matri L; Hamzaoui K; Jeddi A; Miled M; Fki M
Tunis Med; 2007 Jun; 85(6):450-3. PubMed ID: 17644895
[TBL] [Abstract][Full Text] [Related]
24. Smoking and Behçet's disease.
Soy M; Erken E; Konca K; Ozbek S
Clin Rheumatol; 2000; 19(6):508-9. PubMed ID: 11147770
[TBL] [Abstract][Full Text] [Related]
25. Pentoxifylline for the treatment of anterior uveitis in Behcet's disease: possible alternative for TNF blockers.
Appenzeller S; Hazel E
Rheumatol Int; 2011 Nov; 31(11):1511-3. PubMed ID: 20013266
[TBL] [Abstract][Full Text] [Related]
26. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD.
Dalghous AM; Freysdottir J; Fortune F
Scand J Rheumatol; 2006; 35(6):472-5. PubMed ID: 17343257
[TBL] [Abstract][Full Text] [Related]
27. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
[TBL] [Abstract][Full Text] [Related]
28. An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet's syndrome.
Özdede A; Hatemi G
Expert Opin Pharmacother; 2021 Aug; 22(12):1533-1537. PubMed ID: 34218739
[TBL] [Abstract][Full Text] [Related]
29. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
Park JY; Chung YR; Lee K; Song JH; Lee ES
Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-27 gene variant rs153109 is associated with enhanced cytokine serum levels and susceptibility to Behçet's disease in the Iranian population.
Gholijani N; Daryabor G; Kalantar K; Yazdani MR; Shenavandeh S; Zahed M; Jafarpour Z; Malekmakan MR; Amirghofran Z
Eur Cytokine Netw; 2020 Dec; 31(4):140-146. PubMed ID: 33648922
[TBL] [Abstract][Full Text] [Related]
31. Chronic signs of memory B cell activation in patients with Behçet's disease are partially restored by anti-tumour necrosis factor treatment.
van der Houwen TB; van Hagen PM; Timmermans WM; Bartol SJ; Lam KH; Kappen JH; van Zelm MC; van Laar JA
Rheumatology (Oxford); 2017 Jan; 56(1):134-144. PubMed ID: 27744360
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary infiltrates recovered by FK506 in a patient with Behçet's disease.
Koga T; Yano T; Ichikawa Y; Oizumi K; Mochizuki M
Chest; 1993 Jul; 104(1):309-11. PubMed ID: 7686837
[TBL] [Abstract][Full Text] [Related]
33. Effect of Bosentan on Claudication Distance and Endothelium-Dependent Vasodilation in Hispanic Patients With Peripheral Arterial Disease.
De Haro J; Bleda S; Varela C; Esparza L; Acin F;
Am J Cardiol; 2016 Jan; 117(2):295-301. PubMed ID: 26651453
[TBL] [Abstract][Full Text] [Related]
34. Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease : an open-label, single-centre study.
Nanke Y; Kamatani N; Okamoto T; Ogiuchi H; Kotake S
Drugs R D; 2008; 9(6):455-9. PubMed ID: 18989994
[TBL] [Abstract][Full Text] [Related]
35. Regulation of NLRP3 inflammasome by zinc supplementation in Behçet's disease patients: A double-blind, randomized placebo-controlled clinical trial.
Faghfouri AH; Baradaran B; Khabbazi A; Abdoli Shadbad M; Papi S; Faghfuri E; Khajebishak Y; Rahmani S; Tolou Hayat P; Alipour B
Int Immunopharmacol; 2022 Aug; 109():108825. PubMed ID: 35561480
[TBL] [Abstract][Full Text] [Related]
36. Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1beta play a major role in Behçet's synovitis?
Pay S; Erdem H; Pekel A; Simsek I; Musabak U; Sengul A; Dinc A
Rheumatol Int; 2006 May; 26(7):608-13. PubMed ID: 16205926
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: comparison between recurrent aphthous ulcers and the oral ulcers of Behçet's disease.
Lee JH; Jung JY; Bang D
J Eur Acad Dermatol Venereol; 2008 May; 22(5):590-5. PubMed ID: 18093111
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of apremilast and its impact on serum cytokine levels in patients with Behçet's disease.
Wakiya R; Ushio Y; Ueeda K; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
Dermatol Ther; 2022 Aug; 35(8):e15616. PubMed ID: 35668044
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease.
Cantarini L; Lopalco G; Caso F; Costa L; Iannone F; Lapadula G; Anelli MG; Franceschini R; Menicacci C; Galeazzi M; Selmi C; Rigante D
Autoimmun Rev; 2015 Jan; 14(1):1-9. PubMed ID: 25151975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
